Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein Sells 1,066 Shares

by · The Cerbat Gem

Insmed Incorporated (NASDAQ:INSM – Get Free Report) CFO Sara Bonstein sold 1,066 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the transaction, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $7,573,950.36. The trade was a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Sara Bonstein also recently made the following trade(s):

  • On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00.

Insmed Stock Performance

NASDAQ:INSM traded down $0.47 during trading hours on Friday, hitting $65.25. 3,087,759 shares of the company traded hands, compared to its average volume of 1,881,810. The firm has a 50-day moving average of $71.29 and a 200 day moving average of $72.44. The stock has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM – Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.10) earnings per share. On average, analysts forecast that Insmed Incorporated will post -5.44 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Harbor Capital Advisors Inc. grew its stake in shares of Insmed by 237.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company’s stock valued at $4,115,000 after purchasing an additional 41,918 shares during the period. Everence Capital Management Inc. acquired a new position in Insmed during the fourth quarter worth $352,000. Principal Financial Group Inc. lifted its holdings in shares of Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock valued at $136,648,000 after acquiring an additional 214,130 shares during the period. Tidal Investments LLC grew its holdings in shares of Insmed by 447.0% in the 3rd quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company’s stock worth $1,759,000 after purchasing an additional 19,696 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Insmed during the 3rd quarter worth about $248,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on INSM. JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a “buy” rating and issued a $105.00 price target (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. Bank of America increased their price objective on Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 target price on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Check Out Our Latest Analysis on Insmed

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also